Galacto-Oligosaccharide/Polidextrose Enriched Formula Protects against Respiratory Infections in Infants at High Risk of Atopy: A Randomized Clinical Trial

Giusy Ranucci, Vittoria Buccigrossi, Eleonora Borgia, Daniela Piacentini, Federica Visentin, Luigi Cantarutti, Paola Baiardi, Mariagrazia Felisi, Maria Immacolata Spagnuolo, Stefania Zanconato, Eugenio Baraldi, Carlo Giaquinto, Alfredo Guarino

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Early nutrition affects the risk of atopy and infections through modifications of intestinal microbiota. The Prebiotics in the Prevention of Atopy (PIPA) study was a 24-month randomised, double-blind, placebo-controlled trial. It aimed to evaluate the effects of a galacto-oligosaccharide/polydextrose (GOS/PDX)-formula (PF) on atopic dermatitis (AD) and common infections in infants who were born to atopic parents and to investigate the relationship among early nutrition, gut microbiota and clinical outcomes.

METHODS: A total of 201 and 199 infants were randomized to receive a PF and standard formula (SF), respectively; 140 infants remained on exclusive breastfeeding (BF).

RESULTS: The cumulative incidence of AD and its intensity and duration were not statistically different among the three groups. The number of infants with at least one episode of respiratory infection (RI) and the mean number of episodes until 48 weeks of age were significantly lower in the PF group than in the SF group. The number of patients with recurrent RIs and incidence of wheezing lower RIs until 96 weeks were lower in the PF group than the SF group, but similar to the BF group. Bifidobacteria and Clostridium cluster I colonization increased over time in the PF group but decreased in the SF and BF groups. Bifidobacteria had a protective role in RIs, whereas Clostridium cluster I was associated with atopy protection.

CONCLUSION: The early administration of PF protects against RIs and mediates a species-specific modulation of the intestinal microbiota.

TRIAL REGISTRATION: clinicaltrial.gov Identifier: NCT02116452.

Original languageEnglish
JournalNutrients
Volume10
Issue number3
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

atopy
galactooligosaccharides
randomized clinical trials
breast feeding
Oligosaccharides
intestinal microorganisms
Respiratory Tract Infections
atopic dermatitis
Randomized Controlled Trials
Breast Feeding
Clostridium
Bifidobacterium
polydextrose
Atopic Dermatitis
infection
nutrition
incidence
prebiotics
Prebiotics
placebos

Cite this

Galacto-Oligosaccharide/Polidextrose Enriched Formula Protects against Respiratory Infections in Infants at High Risk of Atopy : A Randomized Clinical Trial. / Ranucci, Giusy; Buccigrossi, Vittoria; Borgia, Eleonora; Piacentini, Daniela; Visentin, Federica; Cantarutti, Luigi; Baiardi, Paola; Felisi, Mariagrazia; Spagnuolo, Maria Immacolata; Zanconato, Stefania; Baraldi, Eugenio; Giaquinto, Carlo; Guarino, Alfredo.

In: Nutrients, Vol. 10, No. 3, 01.03.2018.

Research output: Contribution to journalArticle

Ranucci, G, Buccigrossi, V, Borgia, E, Piacentini, D, Visentin, F, Cantarutti, L, Baiardi, P, Felisi, M, Spagnuolo, MI, Zanconato, S, Baraldi, E, Giaquinto, C & Guarino, A 2018, 'Galacto-Oligosaccharide/Polidextrose Enriched Formula Protects against Respiratory Infections in Infants at High Risk of Atopy: A Randomized Clinical Trial', Nutrients, vol. 10, no. 3. https://doi.org/10.3390/nu10030286
Ranucci, Giusy ; Buccigrossi, Vittoria ; Borgia, Eleonora ; Piacentini, Daniela ; Visentin, Federica ; Cantarutti, Luigi ; Baiardi, Paola ; Felisi, Mariagrazia ; Spagnuolo, Maria Immacolata ; Zanconato, Stefania ; Baraldi, Eugenio ; Giaquinto, Carlo ; Guarino, Alfredo. / Galacto-Oligosaccharide/Polidextrose Enriched Formula Protects against Respiratory Infections in Infants at High Risk of Atopy : A Randomized Clinical Trial. In: Nutrients. 2018 ; Vol. 10, No. 3.
@article{af19a3d82e024f0ea5a3f2372382fe54,
title = "Galacto-Oligosaccharide/Polidextrose Enriched Formula Protects against Respiratory Infections in Infants at High Risk of Atopy: A Randomized Clinical Trial",
abstract = "BACKGROUND: Early nutrition affects the risk of atopy and infections through modifications of intestinal microbiota. The Prebiotics in the Prevention of Atopy (PIPA) study was a 24-month randomised, double-blind, placebo-controlled trial. It aimed to evaluate the effects of a galacto-oligosaccharide/polydextrose (GOS/PDX)-formula (PF) on atopic dermatitis (AD) and common infections in infants who were born to atopic parents and to investigate the relationship among early nutrition, gut microbiota and clinical outcomes.METHODS: A total of 201 and 199 infants were randomized to receive a PF and standard formula (SF), respectively; 140 infants remained on exclusive breastfeeding (BF).RESULTS: The cumulative incidence of AD and its intensity and duration were not statistically different among the three groups. The number of infants with at least one episode of respiratory infection (RI) and the mean number of episodes until 48 weeks of age were significantly lower in the PF group than in the SF group. The number of patients with recurrent RIs and incidence of wheezing lower RIs until 96 weeks were lower in the PF group than the SF group, but similar to the BF group. Bifidobacteria and Clostridium cluster I colonization increased over time in the PF group but decreased in the SF and BF groups. Bifidobacteria had a protective role in RIs, whereas Clostridium cluster I was associated with atopy protection.CONCLUSION: The early administration of PF protects against RIs and mediates a species-specific modulation of the intestinal microbiota.TRIAL REGISTRATION: clinicaltrial.gov Identifier: NCT02116452.",
author = "Giusy Ranucci and Vittoria Buccigrossi and Eleonora Borgia and Daniela Piacentini and Federica Visentin and Luigi Cantarutti and Paola Baiardi and Mariagrazia Felisi and Spagnuolo, {Maria Immacolata} and Stefania Zanconato and Eugenio Baraldi and Carlo Giaquinto and Alfredo Guarino",
year = "2018",
month = "3",
day = "1",
doi = "10.3390/nu10030286",
language = "English",
volume = "10",
journal = "Nutrients",
issn = "2072-6643",
publisher = "NLM (Medline)",
number = "3",

}

TY - JOUR

T1 - Galacto-Oligosaccharide/Polidextrose Enriched Formula Protects against Respiratory Infections in Infants at High Risk of Atopy

T2 - A Randomized Clinical Trial

AU - Ranucci, Giusy

AU - Buccigrossi, Vittoria

AU - Borgia, Eleonora

AU - Piacentini, Daniela

AU - Visentin, Federica

AU - Cantarutti, Luigi

AU - Baiardi, Paola

AU - Felisi, Mariagrazia

AU - Spagnuolo, Maria Immacolata

AU - Zanconato, Stefania

AU - Baraldi, Eugenio

AU - Giaquinto, Carlo

AU - Guarino, Alfredo

PY - 2018/3/1

Y1 - 2018/3/1

N2 - BACKGROUND: Early nutrition affects the risk of atopy and infections through modifications of intestinal microbiota. The Prebiotics in the Prevention of Atopy (PIPA) study was a 24-month randomised, double-blind, placebo-controlled trial. It aimed to evaluate the effects of a galacto-oligosaccharide/polydextrose (GOS/PDX)-formula (PF) on atopic dermatitis (AD) and common infections in infants who were born to atopic parents and to investigate the relationship among early nutrition, gut microbiota and clinical outcomes.METHODS: A total of 201 and 199 infants were randomized to receive a PF and standard formula (SF), respectively; 140 infants remained on exclusive breastfeeding (BF).RESULTS: The cumulative incidence of AD and its intensity and duration were not statistically different among the three groups. The number of infants with at least one episode of respiratory infection (RI) and the mean number of episodes until 48 weeks of age were significantly lower in the PF group than in the SF group. The number of patients with recurrent RIs and incidence of wheezing lower RIs until 96 weeks were lower in the PF group than the SF group, but similar to the BF group. Bifidobacteria and Clostridium cluster I colonization increased over time in the PF group but decreased in the SF and BF groups. Bifidobacteria had a protective role in RIs, whereas Clostridium cluster I was associated with atopy protection.CONCLUSION: The early administration of PF protects against RIs and mediates a species-specific modulation of the intestinal microbiota.TRIAL REGISTRATION: clinicaltrial.gov Identifier: NCT02116452.

AB - BACKGROUND: Early nutrition affects the risk of atopy and infections through modifications of intestinal microbiota. The Prebiotics in the Prevention of Atopy (PIPA) study was a 24-month randomised, double-blind, placebo-controlled trial. It aimed to evaluate the effects of a galacto-oligosaccharide/polydextrose (GOS/PDX)-formula (PF) on atopic dermatitis (AD) and common infections in infants who were born to atopic parents and to investigate the relationship among early nutrition, gut microbiota and clinical outcomes.METHODS: A total of 201 and 199 infants were randomized to receive a PF and standard formula (SF), respectively; 140 infants remained on exclusive breastfeeding (BF).RESULTS: The cumulative incidence of AD and its intensity and duration were not statistically different among the three groups. The number of infants with at least one episode of respiratory infection (RI) and the mean number of episodes until 48 weeks of age were significantly lower in the PF group than in the SF group. The number of patients with recurrent RIs and incidence of wheezing lower RIs until 96 weeks were lower in the PF group than the SF group, but similar to the BF group. Bifidobacteria and Clostridium cluster I colonization increased over time in the PF group but decreased in the SF and BF groups. Bifidobacteria had a protective role in RIs, whereas Clostridium cluster I was associated with atopy protection.CONCLUSION: The early administration of PF protects against RIs and mediates a species-specific modulation of the intestinal microbiota.TRIAL REGISTRATION: clinicaltrial.gov Identifier: NCT02116452.

U2 - 10.3390/nu10030286

DO - 10.3390/nu10030286

M3 - Article

C2 - 29494489

VL - 10

JO - Nutrients

JF - Nutrients

SN - 2072-6643

IS - 3

ER -